Sun Pharmaceutical Industries Ltd on Friday said the US health regulatory has approved its LEQSELVI (deuruxolitinib) drug for the treatment of adults with severe alopecia areata.
The approval by the US Food and Drug Administration (USFDA) is for LEQSELVI (deuruxolitinib) 8 mg tablets, Sun Pharma said in a regulatory filing.
Alopecia areata is an autoimmune disorder that can lead to unpredictable hair loss. It occurs when the immune system mistakenly targets hair follicles on the scalp, face, and sometimes other parts of the body, due to a breakdown in immune privilege.